Pharmaceutical company TIOC has established its Zhongshan headquarters and R&D center, marking the sixth major biopharmaceutical project at Zhongshan Life Science Park in 2025. The center focuses on TCR-based protein drugs to pioneer breakthroughs in tumor immunotherapy.

Spanning nearly 1,000 square meters, the center integrates core labs for molecular biology, protein science, tumor immunobiology, and drug process development. This end-to-end infrastructure supports TCR drug development from early-stage research through clinical trials.

TIOC is advancing planning of clinical trials and pipelines, with its lead asset being a fusion protein drug targeting T-cell receptor antigens broadly expressed across multiple solid tumors. The company plans to initiate phase-1 trials for this candidate drug next year, positioning it as the world's first-in-class therapy for this target.